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Abstract
Background: We are investigating the molecular basis of melanoma by defining genomic characteristics that correlate with
tumour phenotype in a novel panel of metastatic melanoma cell lines. The aim of this study is to identify new prognostic
markers and therapeutic targets that might aid clinical cancer diagnosis and management.
Principal Findings: Global transcript profiling identified a signature featuring decreased expression of developmental and
lineage specification genes including MITF, EDNRB, DCT, and TYR, and increased expression of genes involved in interaction
with the extracellular environment, such as PLAUR, VCAN, and HIF1a. Migration assays showed that the gene signature
correlated with the invasive potential of the cell lines, and external validation by using publicly available data indicated that
tumours with the invasive gene signature were less melanocytic and may be more aggressive. The invasion signature could
be detected in both primary and metastatic tumours suggesting that gene expression conferring increased invasive
potential in melanoma may occur independently of tumour stage.
Conclusions: Our data supports the hypothesis that differential developmental gene expression may drive invasive
potential in metastatic melanoma, and that melanoma heterogeneity may be explained by the differing capacity of
melanoma cells to both withstand decreased expression of lineage specification genes and to respond to the tumour
microenvironment. The invasion signature may provide new possibilities for predicting which primary tumours are more
likely to metastasize, and which metastatic tumours might show a more aggressive clinical course.
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Introduction
Melanoma can progress rapidly from a slow-growing surgically
curable lesion to aggressive metastatic disease, with high mortality
and poor response to current therapies [1], but the mechanisms
underlying melanoma progression and resistance to therapeutic
agents are not well understood. There are few treatment options
for melanoma once it has metastasized, and new biomarkers that
aid diagnosis, predict clinical outcome, and suggest new therapies
are required (reviewed in [2]). Surgical, chemical, and biological
therapies offered to patients with metastatic melanoma are all
essentially palliative in nature, with no way of predicting which
patients will benefit. Metastatic melanoma is clinically heteroge-
neous [3,4], with 5-year survival rates of less than 10% for those
patients presenting with disseminated disease [5]. The best chance
of surviving melanoma remains early detection and surgical
resection of the primary tumour.
Melanoma incidence is reported to be increasing globally, with
rates in NewZealand amongst the highestin the world. The lifetime
risk of developing melanoma in fair-skinned New Zealanders is
about 1 in 17 [6]. In 2004, melanoma was the third most common
cancer registration in New Zealand females and fourth for males,
and ranked ninth and sixth respectively in terms of cancer-related
deaths [6]. About 2000 new cases occur annually in New Zealand
with about 250 deaths, and although 50% of melanoma occurs in
those aged over 60, melanoma is the leading cause of cancer deaths
in 15–44 year old New Zealand males [6] resulting in loss of
productive life years. The number of deaths caused by metastatic
melanoma is unlikely to decrease in New Zealand in the near future
as strategies to encourage the early detection of melanoma in New
Zealand have not yet resulted in declining incidence of poorer
prognosis thick primary melanomas [7].
Global gene expression profiling by using microarrays has
proven to be a significant tool in helping to uncover the molecular
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as colorectal and lymphoma, has consistently stratified tumours
into sub-types with prognostic outcomes independent of those
suggested by conventional clinical staging procedures [8,9]. Gene
expression profiling of breast tumours has resulted in sub-
classification of cancers previously thought to be homogenous
[10], allowing prediction of those most likely to benefit from
chemotherapy [11] and overall survival [12]. Gene expression
profiling has generated a number of insights into the molecular
basis of melanoma over the last decade ([13-16]; reviewed in [17]),
but this accumulation of knowledge has yet to provide clinical
benefit in terms of improved patient treatment options or survival.
Weare investigating themolecularbasisof melanomabiologyand
heterogeneity by characterising a novel panel of cell lines developed
largely from New Zealand patients with metastatic melanoma.
Global gene expression analysis showed that the cell lines could be
stratified by differential expression of genes related to melanocyte
development and differentiation, and that lower expression of MITF
and related transcriptional networks combined with higher expres-
sion of environmental interaction genes correlated with increased
invasive potential in vitro. Validation on independent cell line and
tumour data suggests that our gene expression profile is a general
invasion signature in melanoma associated with metastatic potential,
and may occur independently of stage.
Results
Global Transcript Profiling Classified Cell Lines According
to Differential Expression of Developmental and Tissue
Remodelling Genes
After stringent microarray data filtering (Supplementary
Information S1), 572 of the initial ,20,000 transcripts on the
array remained as input for further analysis (Supplementary
Information S1). Unsupervised hierarchical clustering of the
filtered gene list showed two main groups of cell lines (Figure
S1). One of the gene clusters that distinguished the two main
groups showed differential expression of neural crest markers such
as MITF and other genes related to melanocyte development,
differentiation, and function (Figure S1). Given the central role of
MITF in melanocyte development, and the implication of MITF
in melanoma progression, we investigated the consequences of
differential MITF expression in more detail. Class comparison
generated a list of 106 transcripts representing 96 unique genes
that significantly discriminated between higher and lower MITF
cell lines (p,0.001, FDR,1%; Table S1 and Supplementary
Information S1). Hierarchical clustering using only the 106
transcripts identified by class comparison revealed two main
expression motifs in the melanoma cell lines (Figure 1A): Motif 1
distinguished eight cell lines (NZM09, NZM11, NZM19, NZM22,
NZM40, NZM52, SK-MEL-28, UACC62), and consisted of
down-regulation of genes involved in neural crest and melanocyte
development, differentiation, and pigmentation (e.g., EDNRB,
MITF, MLANA, TYR; Table S1), and up-regulation of genes
related to angiogenesis, neurogenesis, immunomodulation, and
interaction and remodelling of the extracellular environment (e.g.,
HIF1a, NRP1, PLAUR, TGFBI; Table S1); Motif 2 distinguished
the remaining 19 cell lines, and showed a pattern of gene
expression that tended to be the inverse of Motif 1, with down-
regulation of extracellular remodelling genes and up-regulation of
MITF and melanocyte lineage markers, although not all Motif 2
cell lines had higher levels of MITF expression (e.g. NZM57). SK-
MEL-28, a melanoma cell line considered to express relatively low
levels of MITF [18], clustered with the lower MITF Motif 1 cell
lines as expected (Figure 1A). One of the Motif 2 cell lines,
NZM04, showed relatively low levels of MITF targets (e.g. DCT,
CDK2, BCL2, GPR143) despite having relatively higher MITF
expression (Figure 1B, C), indicating that there are probably
melanoma sub-types present within the broad Motif 1 and 2
classifications, and that not all cell lines with lower MITF have a
Motif 1 expression profile.
Microarray Validation
Array-based cell line classification was validated by using
quantitative real-time PCR (qPCR), western blotting, and
immunofluoresence on selected cell lines and genes. Unsupervised
clustering of normalised qPCR data separated randomly selected
NZM cells into Motif 1 and 2 groups (Figure 1B). Western blots
confirmed that in addition to MITF, protein levels of MITF
transcriptional targets CDK2, BCL2, and MLANA were also
markedly decreased in lower MITF Motif 1 cell lines (NZM09,
NZM11, NZM40) compared to Motif 2 (Figure 1C). In
accordance with the microarray, qPCR, and western blot data,
immunofluoresence suggested differential expression of both
MITF and MLANA in representative Motif 1 and 2 NZM cells,
with strong nuclear signal for MITF and strong cytoplasmic signal
for MLANA in NZM06 compared to NZM09 (Figure 1D).
Gene Expression Motifs Correlated with Migration
Potential In Vitro
We suspected that lower MITF levels in Motif 1 cell lines
reflected a de-differentiated cell type with higher migratory ability
and therefore invasive potential, and tested this possibility by using
scratch and transwell (Boyden chamber) assays as measures of cell
motility and migration. Motif 1 cell lines showed a 23-fold higher
capacity for migration in transwell assays than Motif 2 cell lines
(Figure 2A), and were significantly faster at wound repair in
scratch assays than Motif 2 cell lines (Figure 2B; Movie S1, Movie
S2). siRNA-mediated MITF knockdown in weakly invasive
NZM06 and NZM15 cells caused an average 4-fold increase in
migration in transwell assays (Figure 2C; Figure S2), confirming
that relative MITF expression was central to the observed
difference in invasive potential between Motif 1 and 2 cell lines,
and consistent with Motif 1 representing an invasion signature for
melanoma cells in vitro. In NZM cells, there was no obvious inverse
relationship between invasive potential and growth rate, as
reported elsewhere [19], with invasive NZM40 cells proliferating
significantly faster than either invasive NZM09 cells or weakly
invasive NZM06 and NZM42 cells (Figure S3).
MITF Correlation with CD200, BRN2, and Genomic Copy
Number
MITF was reported to be regulated by ERK-activating BRAF
mutations [20], so we investigated whether differential MITF
expression could be explained by using CD200 as a proxy for ERK
activation [21]. MITF transcript levels did not correlate with
CD200 expression in NZM cell lines (Figure S3), whereas MLANA,
a transcriptional target of MITF, strongly correlated with MITF
expression as expected (Figure S3). Further, expression of the
POU3F2 (BRN2) transcription factor, which was reported to be a
negative regulator of MITF expression [22], did not inversely
correlate with MITF transcript levels in NZM cell lines (Figure S3).
Genomic amplification of the MITF locus, which may occur in
10–15% of metastatic melanomas [23], was unlikely to underlie
the differential expression of MITF between our Motif 1 and 2
NZM cell lines as there was no difference in MITF copy number
between NZM cell lines with varying levels of relative MITF gene
expression (Figure S3).
Melanoma Invasion Signature
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and Tissue Data
Having shown that our 96-gene invasion signature could predict
invasive potential in vitro, we wished to confirm that our results
represented melanoma-specific differential gene expression by
performing unsupervised hierarchical clustering on a selection of
publicly available data that included both melanoma and non-
melanoma tissue samples. Application of our 96-gene invasion
signature to unsupervised analysis of the Zurich, Mannheim, and
Philadelphia data sets of Hoek et al. [15] could convincingly
recapitulate the weakly and strongly metastatic cell line cohorts
identified by those investigators, (Motif 1=cohort C; Motif
2=cohort A; Figure 3A and B). Conversely, the invasive/
proliferative signature reported by Hoek et al. [15] could group
our NZM cell lines into the same Motif 1 and 2 groups as our
signature (not shown), providing further evidence that a core
network of MITF-mediated gene expression contributes to
invasive potential in melanoma cells. In the combined Zurich
and Philadelphia data, the cohort B cell lines of Hoek et al. [15]
flank the Motif 1 and Motif 2 cell lines (Figure 3A) suggesting they
Figure 1. Expression profiling and validation. (A) Unsupervised hierarchical clustering by using 96 genes identified by class comparison as
differentially expressed between relatively higher or lower MITF-expressing melanoma cell lines classified the cell lines into two main groups (Motif 1,
green label; Motif 2, black label). (B) qPCR validation of selected targets in a subset of Motif 1 and 2 NZM cell lines. Unsupervised clustering of qPCR
data confirmed the Motif 1 (green) and 2 (black) classifications. (C) Protein expression of MITF targets CDK2, BCL2, and MLANA agreed with MITF
transcript levels and array and qPCR cell line stratification. *Motif 1 cell lines. (D) Immunofluorescence showed stronger staining for MITF and MLANA
in the Motif 2 NZM06 cells compared to Motif 1 NZM09 cells.
doi:10.1371/journal.pone.0008461.g001
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2. In the tissue data of Haqq and colleagues [14], our 572 gene list
could clearly cluster melanocytic nevi and skin away from primary
and metastatic melanoma tumour samples (Figure 4A). Our 96-
gene invasion signature further separated the samples into ‘‘skin-
like’’ and ‘‘nevus-like’’ primary and metastatic tumour samples,
which corresponded with Motif 1 or Motif 2 gene expression,
respectively (Figure 4B). Four of five patients reported by Haqq et
al. as ‘‘type 1’’, and to have shorter survival (MM-02, MM-06,
MM-12, MM-14A), had the more invasive Motif 1 gene
expression profile suggesting that less melanocytic tumours with
relatively lower levels of MITF might have worse prognosis.
Further, the primary tumour of patient MM14 of Haqq et al. had
Motif 2 expression whereas a lymph node metastasis from the
same patient showed more invasive Motif 1 expression (Figure 4B).
In the tissue data of Riker et al. [16] the invasion signature genes
correctly classified non-melanoma from melanoma tissue samples,
and grouped primary and metastatic tumours as either Motif 1 and
clustering with invasive A375 cell lines [24], or similar to higher
MITF Motif 2 cell lines NZM12 and NZM15 (Figure S4).
Unsupervised analysis of just the melanoma samples revealed two
main clusters consisting of Motif 1 and Motif 1-like tumours, or
Motif 2 and Motif 2-like tumours (Figure S4). The Motif 1- and 2-
like tumours, like the cohort B cells of Hoek et al., may represent
transitional states of gene expression between the extremes of
invasive Motif 1 and weakly invasive Motif 2. Notably, there was no
clear relationship between expression profile and tumourstage,with
both primary and metastatic tumours showing invasive Motif 1.
Our invasion signature could classify skin, benign nevi, and
primary melanomas in the data of Talantov et al. [25], and like the
Riker and Haqq data, identified nevus-like tumours (Figure S5).
When clustering only tumour samples independently of skin and
nevi in the Talantov data by using our invasion signature genes,
eight primary melanomas exhibited an invasive Motif 1 pattern of
gene expression, with 13 showing a Motif 2 profile (Figure S5).
The nevus-like tumours showed a Motif 1-like expression profile
when compared to just the other tumours (Figure S5), but with
increased expression of some pigmentation genes, e.g. DCT, and
displayed a less marked inverse relationship between lineage
specification and extracellular remodelling genes, which suggested
an alternate or transitional state of invasion-related gene
expression was captured in these samples. Finally, we found high
concordance in the relative expression of our invasion signature
genes when comparing our data with that generated by Folberg
and colleagues in comparing highly invasive with weakly invasive
uveal melanoma cell lines [26] (Supplementary Information S1),
suggesting that the invasion signature is not specific to cutaneous
melanoma.
Discussion
Metastatic melanoma is a clinically heterogeneous disease that
responds unpredictably to treatment, and remains largely
refractory to current therapeutic options. We have been
generating melanoma cell lines in order to develop new therapies
for metastatic melanoma, and to identify markers that might better
predict response to therapy, tumour aggression, and patient
survival. In this study, our gene expression profiling and
knockdown experiments provided evidence that a core network
of MITF-mediated transcription formed a significant component
of a gene signature that correlated with the invasive potential of
metastatic melanoma cell lines in vitro. This is consistent with the
work of other investigators that showed reduced levels of MITF
was associated with increased invasiveness in melanoma cells [27],
whereas MITF over-expression suppressed melanoma metastasis
in mouse xenograft tumours [28]. Further, our data suggests that
acquisition of a more invasive phenotype in melanoma requires
both relative down-regulation of developmental and lineage-
specific pigmentation genes partnered with up-regulation of genes
likely to mediate interaction with the extracellular microenviron-
ment of the tumour.
A number of mechanisms have been postulated to alter MITF
expression in melanoma. BRN2 has been reported to be a negative
regulator of MITF in melanoma cells [22], yet we were unable to
show any correlation between MITF and BRN2 transcription in
this study, with any potential correlation tending towards positive
rather than negative at the transcript level. We found that MITF
transcript levels did not correlate with CD200, a proxy of ERK
activation, which agrees with the conclusions of others that if ERK
activation caused by, for example, BRAF mutation, regulates
MITF expression in melanoma then it is only weakly so at the level
Figure 2. Motif 1 cell lines showed greater motility and migration in vitro. (A) The number of Motif 1 cells (NZM09, NZM11, NZM22, NZM40,
NZM52) that migrated through pored membranes in transwell (Boyden Chamber) assays was approximately 23-fold more than Motif 2 cell lines
(NZM06, NZM12, NZM15, NZM42, NZM45; mean6SD is shown from the combined data of three separate experiments for each cell line; *** p,0.0001,
t test). (B) Motif 1 cell lines NZM09 and NZM40 were significantly faster at wound repair in 2D scratch assays than Motif 2 NZM06 and NZM42 cell lines
(mean6SEM; n=3; *** p,0.001, two-way ANOVA). Representative movies of individual scratch assays for NZM09 and NZM42 are provided as
supplementary Movies S1 and S2, respectively. (C) siRNA-mediated knockdown of MITF caused an almost 4-fold increase in migration of weakly
invasive Motif 2 cell lines (NZM06, NZM15) in transwell assays compared to non-targeting siRNA controls (mean6SD from three separate
experiments; *** p,0.0001, t test). MITF knockdown was confirmed by using qPCR and western blot (Figure S2).
doi:10.1371/journal.pone.0008461.g002
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be responsible for the differential expression of developmental
genes associated with the invasive potential of metastatic
melanoma cells. The regulatory contribution of MITF may be
masked by the combined contribution of these other regulators.
Thirty-five of the genes in our 96-gene invasion signature are
known or predicted targets of MITF [18], and although
experimentally confirmed MITF targets such as MLANA, RAB27A,
and GPR143 corresponded closely with MITF expression in our
data, some did not, suggesting a disconnect in MITF signalling for
some MITF targets in certain melanomas. For example, MITF
was shown to bind and transactivate the HIF1a promoter in mouse
B16 melanoma cells [29], yet in our study HIF1a was inversely
correlated with MITF expression, particularly in the invasive cell
Figure 3. External validation with independent cell line data. Unsupervised clustering by using our 96 gene invasion signature on the
combined Zurich and Philadelphia (A), or Mannheim (B) cell line data of Hoek et al. [15] grouped cell lines into the cohorts of differing invasive
potential originally identified by those authors, with Motif 1 corresponding to strongly invasive cohort C cell lines, and Motif 2 to weakly invasive
cohort A cell lines.
doi:10.1371/journal.pone.0008461.g003
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PLoS ONE | www.plosone.org 5 December 2009 | Volume 4 | Issue 12 | e8461Figure 4. External validation with independent tissue data. (A) Unsupervised analysis by using our filtered gene list (572 transcripts) on the
tissue data of Haqq et al. [14] accurately classified skin, nevus, and melanoma tissue. MN, melanocytic nevus; PM, primary melanoma; MM, metastatic
melanoma. (B) Application of our 96 gene invasion signature to the tissue data of Haqq et al. identified skin-like and nevus-like tumour samples
representing Motif 1- and Motif 2-expressing tumour samples, respectively. Samples in red were derived from patients reported to have ‘‘type 1’’
tumours by the original authors.
doi:10.1371/journal.pone.0008461.g004
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NZM cells, or that B16 cells may not be a good model of human
metastatic melanoma. The inverse correlation between MITF and
HIF1a was also observed upon application of our signature to
independent tumour data suggesting it is a biologically relevant in
vivo. Investigations into whether MITF transcriptional pathways
remain intact in the NZM panel, including whether the putative
PAX3/MITF signalling axis is unaltered in melanoma cells, are
being reported elsewhere (He et al., submitted).
Recently, Hoek et al. [15] published a 105-gene expression
signature able to predict the invasive/proliferative potential of
melanoma cells. There is a 24-gene overlap between our 96-gene
signature and that of Hoek et al., with 18 of the genes in common,
including MITF, involved in melanin biosynthesis, pigmentation,
development, and lineage specification (Supplementary Informa-
tion S1), which reinforces the importance of these pathways in
melanoma. However, the majority of the genes in our invasion
signature are not in common with the Hoek signature, suggesting
we have identified novel genes involved with melanoma invasion.
The differences between the two invasion signatures could reflect
the alternative array platforms, diversity between different
melanoma cell lines upon adaptation to growth in vitro, or intrinsic
tumour heterogeneity.
A number of the differentially expressed transcripts in our
invasion signature that are involved in interaction and remodelling
of the extracellular environment have previously been associated
with increased malignancy or worse prognosis in cancer. The
metastasis-associated gene S100A4 showed increased expression in
invasive melanoma cell lines in this study, with S100A4 over-
expression previously associated with a poor prognosis in a variety
of human neoplasms such as stomach, colon, breast, melanoma,
gallbladder, and pancreatic cancer (reviewed in [30]). S100A4
may mediate invasive potential by regulating matrix metallopro-
teinases and tissue inhibitors of matrix metalloproteinases such as
TIMP2 [31]. TIMP2 is involved in matrix degradation and
invasion, and is down-regulated in Motif 1 cell lines in this study,
which is consistent with its role in inhibiting matrix metallopro-
teinases, and agrees with the inverse correlation shown between
S100A4 and TIMP2 in osteosarcoma cells [31]. Further, over-
expression of TIMP2 in tumour stroma was associated with
increased disease-free survival in prostate cancer [32], and down-
regulation of MMP2 by TIMP2 over-expression reduced tumour
growth and metastatic potential in a rat model of breast cancer-
associated brain metastasis [33]. Transcripts of the extracellular
matrix protein TGFBI were elevated in our more invasive cell
lines. TGFBI has been identified as a member of a metastasis
network in oesophageal squamous cell carcinoma [34], with higher
expression noted in renal, gastrointestinal, and brain tumours [35],
and linked to increased metastatic potential and poorer prognosis
in colon cancer [36]. VCAN expression is elevated in our invasive
Motif 1 NZM cells, which is in agreement with a recent report that
VCAN is up-regulated in invasive human melanoma cells via a
TCF4/AP1-mediated mechanism [37].
Pathway analysis by using our invasion signature genes linked
networks that connect hypoxia to invasive potential (Figure 5),
which provides additional strength to the suggestion that hypoxia
may be a significant driver of phenotype switching in melanoma
[19] and contributes to melanoma progression [38]. Hypoxia can
promote lymph node metastasis via up-regulation of PLAUR [39],
and up-regulation of HIF1a, JUN and PLAUR in our invasive cell
lines hints at possible activation of JUN/AP1 and HIF/ARNT
pathways in melanoma (Figure 5). The presence of differential
signature gene expression in in vivo data suggests that relative
expression of oxygen-responsive genes is not simply a consequence
of the adaptation of NZM tumour cells to culture in our model
system, but is likely a snapshot of prevailing transcription at the
time the tumour sample was removed.
The identification of skin-like and nevus-like primary and
metastatic tumours in the data of Haqq, Riker, and Talantov that
corresponded with more or less invasive patterns of gene
expression respectively, bolsters our initial suggestion that invasive
Motif 1 NZM cells with relative depression of pigmentation gene
transcription probably reflected a more de-differentiated and less
melanocytic cell type than Motif 2. Further, this also suggests that
invasive potential may not evolve solely as a function of melanoma
stage and progression, but may exist early in the transformation
process and act to prime neoplastic cells for metastatic invasion in
response to certain environmental queues, e.g. hypoxia. Con-
versely, those tumours with a Motif 2 signature gene profile appear
to have relatively intact signalling pathways that control
pigmentation and differentiation, similar to that operating in
normal nevi, and may not be as responsive to changes in the
tumour microenvironment, resulting in reduced invasive capacity.
However, the fact remains that Motif 2 NZM cell lines, despite
being relatively less invasive than Motif 1 cells, were derived from
metastatic melanoma samples, and had thus gained an invasive
phenotype at some point during tumourigenesis. This supports the
notion of phenotype switching proposed by Hoek and colleagues,
which suggests invasive potential is a dynamic, non-linear process
that transitions from more to less invasive states depending on the
microenvironment encountered by the tumour during the course
of disease progression.
The ability of our invasion signature to classify tumour and cell
line transcription in multiple data sets is compelling evidence that
our in vitro-derived motifs represent patterns of differential gene
expression that may define invasive capacity of melanoma cells in
vivo. However, although Motif 1 and Motif 2 classification - which
probably represent the extremes of the invasive phenotype - can
easily and reproducibly be found in publicly available data, the
lack of corresponding clinical data that might give clues to the
prognosis and aggression of the tumours means that we are as yet
unable to confirm whether our invasion signature is a stage-
independent indicator of metastatic potential and survival.
Nonetheless, this study has identified a number of genes involved
in development, lineage specification, and interaction with the
tumour microenvironment that may drive invasion, and could be
new targets for improved monitoring and treatment of metastatic
melanoma, the significance of which we aim to investigate in
future studies.
Materials and Methods
Cell Lines
The 25 NZM cell lines used for this study were generated from
ethically consented and pathologically confirmed metastatic
melanoma samples as previously described [40,41], and grown
at 37uC (5% C02) in MEM-alpha media (Invitrogen) supplement-
ed with 5% foetal calf serum (FCS) and 1% insulin-tranferrin-
selenium (Roche). UACC62 and SK-MEL-28 were obtained from
ATCC and grown in DMEM (Invitrogen) containing 10% FCS
and 1% penicillin/streptomycin. NZM01 and NZM02 were
derived from different tumours from the same patient at different
surgeries. NZM07.2 (p53 mutant) and NZM07.4 (p53 wild type)
were subsequently derived from the parental NZM07 cell line.
In Vitro Motility and Migration Assays, siRNA Transfection
For motility assays, randomly chosen Motif 1 (NZM09,
NZM40) or Motif 2 (NZM06, NZM42) cells were grown to
Melanoma Invasion Signature
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200 mL plastic pipette tip, then transferred to a heated-stage
assembly on an Olympus IX71 inverted microscope. Scratch
closure was captured by time-lapse photography over 3 days.
Scratch assays were quantified by generating still images from the
time-lapse movie at specific time-points with Imovie (Apple Inc.),
and scratch area measured by using a pixel intensity threshold
with ImageJ software [42] that allowed exclusion of cells that had
migrated into the scratch from the surface area calculation.
Representative time-lapse movies of faster-migrating NZM09 cells
and slower-migrating NZM42 cells are provided as supplementary
Movie S1 (NZM09) and Movie S2 (NZM42).
For migration assays, all adherent Motif 1 NZM cell lines
(NZM09, NZM11, NZM22, NZM40, NZM52) and five randomly
chosen Motif 2 cell lines (NZM06, NZM12, NZM15, NZM42,
NZM45) were used, with 1610
5 cells seeded into transwell inserts
with 8 mm micropore filters (Becton Dickinson) in 200 mL media.
Media containing 10% FCS was added to the lower chamber as
chemoattractant. After 24 hours, cells on the upper side of the
filter were removed with a cotton swab, with the remaining cells
fixed and stained using a standard haematoxylin and eosin
protocol, then imaged by using an Olympus IX71 inverted
microscope. Five random fields of view were captured per
transwell insert, and the number of cells that had migrated to
the bottom side of the membrane was counted by using the
particle counting module of ImageJ after size and pixel intensity
thresholding. Each assay was repeated in three independent
experiments resulting in 15 fields of view for each cell line. siRNA-
mediated knockdown of MITF was performed in two randomly
chosen Motif 2 cell lines (NZM06, NZM15) by using reverse
transfection with Lipofectamine RNAiMAX (Invitrogen) and a
pre-designed siRNA targeting MITF (Ambion) according to the
manufacturer’s instructions, with a final siRNA concentration of
5 nM. MITF knockdown was confirmed by using qPCR and
western blotting. Non-targeting negative control experiments were
performed by using an siRNA against the non-mammalian
Figure 5. A model linking expression of lineage specification and extracellular sensing genes to invasive potential in melanoma.
Pathway analysis suggested that melanoma invasive potential may be mediated by the intersection of MITF-driven transcriptional networks with
pathways involved in HIF/JUN activation and response to hypoxia.
doi:10.1371/journal.pone.0008461.g005
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siRNA targets sequences were: MITF (Ambion ID#: 3816), 59-
GGACAAUCACAACCUGAUUtt-39; Luciferase, (Dharmacon),
59-AACGUACGCGGAAUACUUCGAtt-39. Cells were exposed
to transfection reagents for 24 hours before re-seeding into
transwell inserts for migration assays, as described above, with
migrated cells measured 48 hours post-transfection.
Cell Proliferation
Proliferation of cell lines was measured by using an MTT cell
proliferation kit (Roche) according to the manufacturer’s instruc-
tions. Cells (5610
5) were seeded in 96-well plates, and incubated
for 24, 48, or 72 hours. Ten mL of MTT reagent (5 mg/mL in
PBS) was added to each well and incubated for 4 hours at 37uC.
The resulting formazan product within the cells was dissolved in
100 mL of 10% SDS in 0.01 M HCl. Optical density (570 nm) was
measured by using a PolarStar Optima micro plate reader.
RNA Isolation and Amplification
Total RNA was isolated from cultured cells by using a
combination of Tri Reagent (MRC) and column-based purifica-
tion (RNeasy, Qiagen; or Purelink, Invitrogen) according to the
manufacturer’s instructions (a detailed protocol is available at
http://openwetware.org/wiki/Eccles:RNA_extraction_AJ). Total
RNA was eluted in nuclease-free water, quantified by using a
Nanodrop ND-1000 spectrophotometer, then subjected to quality
assessment by using an Agilent Bioanalyzer 2100. The Bioanalyzer
RNA Integrity Number (RIN) ranged from 8.8–10 for all RNA
samples. Antisense RNA (aRNA) was generated from 500 ng total
RNA by using an Amino Allyl MessageAmp II amplification kit
(Ambion) according to the manufacturer’s instructions. For
Affymetrix arrays, 200 ng of total RNA was amplified by using
a MessageAmp Premiere kit (Ambion) according to the manufac-
turer’s instruction.
Reverse Transcription and Quantitative PCR
cDNA was generated from 100 ng total RNA by using
SuperScript III (Invitrogen) according to the manufacturer’s
instructions. Transcript abundance was measured by using
Platinum SYBR Green qPCR SuperMix-UDG with ROX
reference dye (Invitrogen) on an ABI 7300 Real-Time PCR
System. qPCR reactions were performed in duplicate with 2.5 ng
template cDNA (RNA equivalent) per 20 uL reaction. Cycling
conditions were 50uCf o r2m i n . ,9 5 uC for 2 min., then 40 cycles
of 95uC for 15 sec./60uC for 1 min., followed by melting curve
analysis. For validation of microarray results, comparative qPCR
was performed for selected genes on randomly chosen NZM cell
lines, with quantification cycle (Cq) values normalised to total
RNA input and converted to quantities relative to the cell line
with the lowest abundance of a given gene by using the delta-Cq
method. qPCR was performed on different RNA samples to
those used for microarray analysis. For MITF genomic copy
number measurements, DNA was extracted from NZM cells by
using a Purelink Genomic DNA Mini Kit (Invitrogen), with 2 ng
genomic DNA used as template for qPCR, and qPCR reagents
and cycling conditions as described above for transcript
measurement. MITF genomic copy number was normalised to
LINE1 copy number [43] and expressed relative to a normal
human DNA sample by using qBase software and the delta-delta-
Cq method. The normal genomic DNA sample was kindly
provided by Prof. Stephen Robertson (University of Otago). All
primer sequences used for this study are provided in Supple-
mentary Information S1.
Microarray Hybridisation
Spotted oligonucleotide microarrays were generated at the
Otago Genomics Facility (University of Otago) by printing a
human 20K oligonucleotide set (MWG Biotech) onto epoxy-
coated slides (Schott) using an ESI arrayer. Arrays were blocked
immediately before use by pre-hybridisation at 42uC (60 min.) in
1% BSA, 56SSC, 0.1% SDS. Five ug of Alexa-647-labelled
melanoma cell line aRNA was combined with 5 ug Alexa-555-
labelled common universal human reference aRNA (Stratagene),
fragmented, vacuum concentrated, re-suspended in SlideHyb
Glass Array Hybridization Buffer #1 (Ambion), then hybridised to
the array under 22 mm650 mm LifterSlips (Erie) for 20 hours at
42uC inside a DeRisi-design hybridisation chamber (Monterey
Industries). Arrays were washed with 2 x SSC/0.2% SDS (5 min.),
2 x SSC (5 min.), and 0.2 x SSC, dried by centrifugation (200 g,
3 min.), then imaged on an Axon 4000B array scanner. To assess
variation in batches of array hybridisations and common reference
RNA, replicate hybridisations of RNA from selected cell lines were
performed that spanned different hybridisations done at different
times with different batches of common reference RNA. RNA for
the replicate cell lines was from different biological samples. Two
of the cell lines, NZM12 and NZM15, were used for microarray
profiling on Affymetrix U133 Plus 2.0 GeneChips, in which
200 ng of Total RNA was amplified by using a MessageAmp
Premiere kit (Ambion), with 10-15 ug of biotinylated cRNA used
for hybridisation. Affymetrix RNA amplification, hybridisation,
washing, and scanning were performed at the Centre for
Genomics and Proteomics, University of Auckland.
Gene Expression Data Analysis
Fluorescent intensity data was extracted by using GenePix Pro
5.0 software, then imported into BRB ArrayTools 3.60 (developed
by Dr Richard Simon and Amy Peng Lam, http://linus.nci.nih.
gov/BRB-ArrayTools.html) for normalisation (print-tip group
lowess smoothing) and data filtering. Genes were excluded if
flagged as bad or absent by GenePix, were below an intensity of
150 in both channels, were missing or filtered from more than
50% of the arrays, or did not vary 2-fold or more from the mean
value in at least 20% of the arrays (data-filtering outlined in
Supplementary Information S1). Class comparison was performed
by using the Class Comparison module of BRB ArrayTools.
Unsupervised hierarchical clustering of filtered, normalised, and
median-centred log2-transformed data was performed by using
GenePattern [44] with a Pearson correlation distance measure and
an average linkage clustering method, and viewed by using Java
TreeView 1.1.1 [45]. After normalisation and filtering, all replicate
samples clustered together, including different cell lines from
different tumours from the same patient (NZM01, NZM02) and
derivative cell lines (NZM07, NZM07.2, NZM07.4), with no
scaling required to control for batch-specific biases. The data
discussed in this publication have been deposited in NCBI’s Gene
Expression Omnibus [46] and are accessible through GEO Series
accession numbers GSE16249 (Affymetrix data; http://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc=GSE16249) and GSE16404
(spotted array data; http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE16404).
For validation on independent melanoma data sets, Affymetrix
array data was imported from GEO into GenePattern as either the
original CEL files [15,16,47,48] or as MAS5-normalised SOFT-
formatted data files [25]. CEL files were RMA-normalised by
using the ExpressionFileCreator module of GenePattern. Expres-
sion values for the specific NZM signature genes were extracted by
using the SelectFeaturesRows GenePattern module and submitted
to hierarchical clustering as log-transformed median-centred data
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array data of Haqq et al. was used as provided by the authors in
Supplementary Table 10 of their paper [14], and converted to a
GenePattern GCT-formatted file for gene extraction and
hierarchical clustering (Pearson correlation, average linkage,
median-centred). Missing data imputation was performed by
using the ImputeMissingValues.KNN module of GenePattern.
Gene ontology and pathway construction was performed by using
GATHER [49], Cell Illustrator Online v4.0, and Ingenuity
Pathway Analysis v12.2, with permutation analysis to estimate
false discovery at the pathway level.
Western Blotting and Immunofluorescence
The steps for protein preparation, electrophoresis and blotting
onto nitrocellulose membrane (Amersham) were the same as stated
previously [50] except that blotting was carried out using a
Western Breeze Immunodetection Kit (Invitrogen). After blocking,
the membrane was probed with a primary antibody to either
MITF (Zymed; 1:1000), CDK2 (Santa Cruz; 1:2000), BCL2
(Santa Cruz; 1:1000), MLANA (Santa Cruz; 1:5000). or B-Actin
(Sigma; 1:20000). The membrane was then washed, incubated
with secondary antibody, then incubated with chemiluminescence
luminol reagents according to the manufacturer’s directions. The
amplified signals were then detected with Kodak X-OMAT AR
film.
For immunofluorescence using cell lines, cells grown to 50%
confluency on glass coverslips were rinsed with PBS, and fixed
with 4% paraformaldehyde in PBS for 15 min. at room
temperature. Coverslips were rinsed with PBS before incubation
with 1% BSA in PBS for 30 min. to block non-specific antibody
binding, then incubated for 60 min. at room temperature with
either mouse monoclonal anti-MLANA antibody, Santa Cruz), or
mouse monoclonal anti-MITF antibody (clone C5+D5, Zymed).
After rinsing three times with PBS, the coverslips were
subsequently incubated with Alexa Fluor 568 goat anti-mouse
secondary antibody (Molecular Probes, 1:2000) in 0.3% BSA in
PBS for 30 min. at room temperature in the dark, washed with
PBS, and mounted with DAPI (4V,6-diamidino-2-phenylindole)–
containing fluorescence mounting solution (Vector Laboratories).
Negative control incubations using the same secondary antibody,
but omitting the primary antibody were also carried out and
showed negative staining. Images were captured by using SPOT
v4.6 software and a SPOT RT-SE 6 Slider digital camera
(Diagnostic Instruments) connected to a Zeiss Axioplan micro-
scope equipped with an X-Cite 120 fluorescent light source
(EXFO).
Supporting Information
Table S1 The 96 genes identified by class comparison as
significantly differentially expressed between higher and lower
MITF melanoma cell lines, ranked by log2 ratio.
Found at: doi:10.1371/journal.pone.0008461.s001 (0.04 MB
XLS)
Supplementary Information S1 Data filtering; filtered gene
list; class comparison; comparison with Hoek et al. signature;
comparison with Folberg et al. data; primers used for qPCR.
Found at: doi:10.1371/journal.pone.0008461.s002 (0.67 MB
XLS)
Figure S1 Unsupervised hierarchical clustering of metastatic
melanoma cell lines by using the filtered list of 572 genes.
Found at: doi:10.1371/journal.pone.0008461.s003 (0.54 MB
PDF)
Figure S2 siRNA-mediated MITF knockdown in weakly
invasive NZM cells.
Found at: doi:10.1371/journal.pone.0008461.s004 (0.15 MB
PDF)
Figure S3 Proliferation; MITF correlation with BRN2, CD200,
and MLANA; and MITF genomic copy number.
Found at: doi:10.1371/journal.pone.0008461.s005 (0.12 MB
PDF)
Figure S4 Unsupervised clustering of invasion signature genes in
the tissue data of Riker et al.
Found at: doi:10.1371/journal.pone.0008461.s006 (0.75 MB
PDF)
Figure S5 Unsupervised clustering of skin, benign nevi, and
primary melanoma data from Talantov et al.
Found at: doi:10.1371/journal.pone.0008461.s007 (0.40 MB
PDF)
Movie S1 Time-lapse movie of a scratch assay for NZM09, a
fast-migrating Motif 1 cell line.
Found at: doi:10.1371/journal.pone.0008461.s008 (1.63 MB
MOV)
Movie S2 Time-lapse movie of a scratch assay for NZM42, a
slow-migrating Motif 2 cell line.
Found at: doi:10.1371/journal.pone.0008461.s009 (1.64 MB
MOV)
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